European Journal of Cancer
Volume 39, Issue 9 , Pages 1194-1198, June 2003

Levels of absolute survival benefit for systemic therapies of advanced cancer:

a call for standards

  • J.P.A. Ioannidis

      Affiliations

    • Clinical Trials and Evidence-Based Medicine Unit, Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina 45110, Greece
    • Division of Clinical Care Research, Tufts-New England Medical Center, Boston, MA, USA
    • ,
  • N. Pavlidis

      Affiliations

    • Division of Medical Oncology, Department of Medicine (NP), University of Ioannina School of Medicine, Ioannina 45110, Greece
    • Corresponding Author InformationCorresponding author. Tel.: +30-2-6510-97505

Received 3 January 2003; accepted 8 January 2003.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

PII: S0959-8049(03)00119-9

doi:10.1016/S0959-8049(03)00119-9

European Journal of Cancer
Volume 39, Issue 9 , Pages 1194-1198, June 2003

Article Tools